H.C. Wainwright Thinks Oxford BioMedica’s Stock is Going to Recover
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Oxford BioMedica (OXBDF – Research Report) today and set a price target of £24.00. The company's shares closed last Wednesday at $5.47,...
Oxford Biomedica (OXB): Vector Innovation Key to Cell and Gene Evolution
LONDON, UK / ACCESSWIRE / October 5, 2020 / Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component...